More on CYTR

- Summary
- Chart
- Profile
- Historical


- Earnings
- Ratings
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (8/6/15 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

CYTR Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 28.05M
Marketable securities 37.1M
Proceeds from sale of RXi, received January 6, 2011
Receivable 5.15M
Investment in Adventrx Pharmaceuticals, at market
Income taxes recoverable
Interest receivable 76.25K
Prepaid expenses and other current assets 930.28K
Total current assets 71.31M
Equipment and furnishings, net 949.31K
Goodwill 183.78K
Other assets 1.32M
Total assets 73.77M
Current liabilities:
Accounts payable 4.64M
Accrued expenses and other current liabilities 10.35M
Warrant liabilities 7M
Total current liabilities 21.99M
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding 0
Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 55.92K
Additional paid-in capital 378.36M
Accumulated comprehensive income, net of tax
Treasury stock, at cost (633,816 shares) -2.61M
Accumulated deficit -324.03M
Total stockholders' equity 51.77M
Total liabilities and stockholders' equity 73.77M